An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

NCT ID: NCT00730171

Last Updated: 2018-02-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1743 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants include randomization-ineligible (RI) patients from the lead-in double-blind trials MCP-103-302 (NCT00938717) or MCP-103-303 (NCT00730015), or rollover (RO) patients from the lead-in double-blind trials MCP-103-302 (NCT00938717), MCP-103-303 (NCT00730015), and from the Phase 2 double-blind studies MCP-103-004 (NCT00306748), MCP-103-005 (NCT00258193), and MCP-103-201 (NCT00402337), or MCP-103-202 (NCT00460811).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome With Constipation Chronic Constipation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Linaclotide

Linaclotide 290 μg/day capsules, administered orally once daily for up to 78 weeks. Dose reduction to 145 μg/day was permitted at the discretion of the Investigator.

Group Type EXPERIMENTAL

Linaclotide

Intervention Type DRUG

Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Linaclotide

Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Linzess

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have

* entered study MCP-103-303 or MCP-103-302 and at minimum completed the pre-treatment period or
* completed one of the following studies: MCP-103-004, MCP-103-005, MCP-103-201, MCP-103-202
* Sexually active patients of childbearing potential agree to use birth control
* Females of childbearing potential must have a negative urine pregnancy test prior to dosing
* Lactating females must agree not to breastfeed
* Patient must meet protocol criteria for CC or IBS-C

Exclusion Criteria

* Patient must not use protocol-defined prohibited medicine
* Patient is planning to receive an investigational drug at any time during the study
* Patient has an unresolved adverse events or a clinically significant finding on a physical examination, 12-lead electrocardiogram, or clinical laboratory test
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Forest Laboratories

INDUSTRY

Sponsor Role collaborator

Ironwood Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeffrey M. Johnston, MD, FACP

Role: STUDY_CHAIR

Ironwood Pharmaceuticals, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ironwood Investigational Site

Birmingham, Alabama, United States

Site Status

Ironwood Investigational Site

Huntsville, Alabama, United States

Site Status

Ironwood Investigational Site

Chandler, Arizona, United States

Site Status

Ironwood Investigational Site

Phoenix, Arizona, United States

Site Status

Ironwood Investigational Site

Tucson, Arizona, United States

Site Status

Ironwood Investigational Site

Tucson, Arizona, United States

Site Status

Ironwood Investigational Site

Tucson, Arizona, United States

Site Status

Ironwood Investigational Site

Sherwood, Arkansas, United States

Site Status

Ironwood Investigational Site

Anaheim, California, United States

Site Status

Ironwood Investigational Site

Chula Vista, California, United States

Site Status

Ironwood Investigational Site

Encinitas, California, United States

Site Status

Ironwood Investigational Site

Garden Grove, California, United States

Site Status

Ironwood Investigational Site

Laguna Hills, California, United States

Site Status

Ironwood Investigational Site

Los Angeles, California, United States

Site Status

Ironwood Investigational Site

Orange, California, United States

Site Status

Ironwood Investigational Site

Sacramento, California, United States

Site Status

Ironwood Investigational Site

San Carlos, California, United States

Site Status

Ironwood Investigational Site

San Diego, California, United States

Site Status

Ironwood Investigational Site

San Diego, California, United States

Site Status

Ironwood Investigational Site

San Diego, California, United States

Site Status

Ironwood Investigational Site

Colorado Springs, Colorado, United States

Site Status

Ironwood Investigational Site

Bristol, Connecticut, United States

Site Status

Ironwood Investigational Site

Boynton Beach, Florida, United States

Site Status

Ironwood Investigational Site

Hollywood, Florida, United States

Site Status

Ironwood Investigational Site

Inverness, Florida, United States

Site Status

Ironwood Investigational Site

Jacksonville, Florida, United States

Site Status

Ironwood Investigational Site

Jacksonville, Florida, United States

Site Status

Ironwood Investigational Site

Lauderdale Lakes, Florida, United States

Site Status

Ironwood Investigational Site

Miami, Florida, United States

Site Status

Ironwood Investigational Site

Pinellas Park, Florida, United States

Site Status

Ironwood Investigational Site

Port Orange, Florida, United States

Site Status

Ironwood Investigational Site

Tampa, Florida, United States

Site Status

Ironwood Investigational Site

Newnan, Georgia, United States

Site Status

Ironwood Investigational Site

Peoria, Illinois, United States

Site Status

Ironwood Investigational Site

Anderson, Indiana, United States

Site Status

Ironwood Investigational Site

Clive, Iowa, United States

Site Status

Ironwood Investigational Site

Davenport, Iowa, United States

Site Status

Ironwood Investigational Site

Mission, Kansas, United States

Site Status

Ironwood Investigational Site

Overland Park, Kansas, United States

Site Status

Ironwood Investigational Site

Topeka, Kansas, United States

Site Status

Ironwood Investigational Site

Baton Rouge, Louisiana, United States

Site Status

Ironwood Investigational Site

Metairie, Louisiana, United States

Site Status

Ironwood Investigational Site

Monroe, Louisiana, United States

Site Status

Ironwood Investigational Site

Shreveport, Louisiana, United States

Site Status

Ironwood Investigational Site

Annapolis, Maryland, United States

Site Status

Ironwood Investigational Site

Baltimore, Maryland, United States

Site Status

Ironwood Investigational Site

Hollywood, Maryland, United States

Site Status

Ironwood Investigational Site

Laurel, Maryland, United States

Site Status

Ironwood Investigational Site

Chesterfield, Michigan, United States

Site Status

Ironwood Investigational Site

Traverse City, Michigan, United States

Site Status

Ironwood Investigational Site

Troy, Michigan, United States

Site Status

Ironwood Investigational Site

Plymouth, Minnesota, United States

Site Status

Ironwood Investigational Site

Jackson, Mississippi, United States

Site Status

Ironwood Investigational Site

Tupelo, Mississippi, United States

Site Status

Ironwood Investigational Site

Jefferson City, Missouri, United States

Site Status

Ironwood Investigational Site

Henderson, Nevada, United States

Site Status

Ironwood Investigational Site

Las Vegas, Nevada, United States

Site Status

Ironwood Investigational Site

Cedar Knolls, New Jersey, United States

Site Status

Ironwood Investigational Site

Marlton, New Jersey, United States

Site Status

Ironwood Investigational Site

Ocean City, New Jersey, United States

Site Status

Ironwood Investigational Site

Albuquerque, New Mexico, United States

Site Status

Ironwood Investigational Site

Mineola, New York, United States

Site Status

Ironwood Investigational Site

Pittsford, New York, United States

Site Status

Ironwood Investigational Site

Asheboro, North Carolina, United States

Site Status

Ironwood Investigational Site

Asheville, North Carolina, United States

Site Status

Ironwood Investigational Site

Chapel Hill, North Carolina, United States

Site Status

Ironwood Investigational Site

Charlotte, North Carolina, United States

Site Status

Ironwood Investigational Site

Greensboro, North Carolina, United States

Site Status

Ironwood Investigational Site

Harrisburg, North Carolina, United States

Site Status

Ironwood Investigational Site

Hickory, North Carolina, United States

Site Status

Ironwood Investigational Site

Huntersville, North Carolina, United States

Site Status

Ironwood Investigational Site

Jacksonville, North Carolina, United States

Site Status

Ironwood Investigational Site

New Bern, North Carolina, United States

Site Status

Ironwood Investigational Site

Statesville, North Carolina, United States

Site Status

Ironwood Investigational Site

Summerville, North Carolina, United States

Site Status

Ironwood Investigational Site

Wilmington, North Carolina, United States

Site Status

Ironwood Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Ironwood Investigational Site

Beachwood, Ohio, United States

Site Status

Ironwood Investigational Site

Cincinnati, Ohio, United States

Site Status

Ironwood Investigational Site

Cincinnati, Ohio, United States

Site Status

Ironwood Investigational Site

Dayton, Ohio, United States

Site Status

Ironwood Investigational Site

Mentor, Ohio, United States

Site Status

Ironwood Investigational Site

Sylvania, Ohio, United States

Site Status

Ironwood Investigational Site

Wadsworth, Ohio, United States

Site Status

Ironwood Investigational Site

Zanesville, Ohio, United States

Site Status

Ironwood Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

Ironwood Investigational Site

Yukon, Oklahoma, United States

Site Status

Ironwood Investigational Site

Lancaster, Pennsylvania, United States

Site Status

Ironwood Investigational Site

Lancaster, Pennsylvania, United States

Site Status

Ironwood Investigational Site

Levittown, Pennsylvania, United States

Site Status

Ironwood Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

Ironwood Investigational Site

Sellersville, Pennsylvania, United States

Site Status

Ironwood Investigational Site

Anderson, South Carolina, United States

Site Status

Ironwood Investigational Site

Charleston, South Carolina, United States

Site Status

Ironwood Investigational Site

Simpsonville, South Carolina, United States

Site Status

Ironwood Investigational Site

Bristol, Tennessee, United States

Site Status

Ironwood Investigational Site

Chattanooga, Tennessee, United States

Site Status

Ironwood Investigational Site

Germantown, Tennessee, United States

Site Status

Ironwood Investigational Site

Kingsport, Tennessee, United States

Site Status

Ironwood Investigational Site

Nashville, Tennessee, United States

Site Status

Ironwood Investigational Site

Beaumont, Texas, United States

Site Status

Ironwood Investigational Site

El Paso, Texas, United States

Site Status

Ironwood Investigational Site

Fort Worth, Texas, United States

Site Status

Ironwood Investigational Site

Houston, Texas, United States

Site Status

Ironwood Investigational Site

Irving, Texas, United States

Site Status

Ironwood Investigational Site

Longview, Texas, United States

Site Status

Ironwood Investigational Site

San Antonio, Texas, United States

Site Status

Ironwood Investigational Site

Sugar Land, Texas, United States

Site Status

Ironwood Investigational Site

Ogden, Utah, United States

Site Status

Ironwood Investigational Site

Salt Lake City, Utah, United States

Site Status

Ironwood Investigational Site

Chesapeake, Virginia, United States

Site Status

Ironwood Investigational Site

Lynchburg, Virginia, United States

Site Status

Ironwood Investigational Site

Spokane, Washington, United States

Site Status

Ironwood Investigational Site

Vancouver, Washington, United States

Site Status

Ironwood Investigational Site

La Crosse, Wisconsin, United States

Site Status

Ironwood Investigational Site

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MCP-103-305

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Long Term Safety Study of Plecanatide
NCT02706483 COMPLETED PHASE3